Aktienanalyse zu Apollomics Inc (APLM)APLMApollomics Inc

Apollomics Inc. is a clinical-stage biopharmaceutical company focusing on discovering and developing oncology therapies to address unmet medical needs, especially for difficult-to-treat and treatment-resistant cancers. The product candidates in its pipeline are categorized into two groups based on their mechanisms of action, each of which contains product candidates at different stages of development: tumor inhibitors and immuno-oncology drugs. Its tumor inhibitor product candidates consist of three small-molecule inhibitors against different uncontrolled growth signaling pathways in cancer cells: vebreltinib, APL-102 and APL-122. Its three immuno-oncology product candidates consist of APL-501, APL-502 and APL-80. Vebreltinib is a potent, oral active selective c-Met inhibitor. APL-102 is an oral active, small molecule Multiple Tyrosine Kinase Inhibitor. APL-122 is a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathways. APL-501 is an anti-PD-1 antibody product candidate. It operates in the Financials sector (PHARMACEUTICAL PREPARATIONS industry).

Apollomics Inc. (APLM) is a good buy right now, trading at $26.60 with a strong 1-year change of +531.83%. The RSI is at 77.754, indicating strong momentum, while the stock has shown a remarkable 54.25% increase over the last 20 days. However, the main risk is the negative EPS forecast of -52.80 for Q4 2024, which could affect investor sentiment in the long term.